BIRMINGHAM, Ala., May 28 /PRNewswire/ -- Atherotech, Inc., a cardio-diagnostic company, today announced it will be exhibiting its VAP Cholesterol Test in booth No. 4202 at the American Diabetes Association 68th Annual Scientific Sessions. The annual meeting takes place June 6 - 10, 2008, at the Moscone Convention Center in San Francisco.
The VAP(R) Cholesterol Test (Atherotech, Inc.) is the only commercially available advanced lipid profile that routinely reports all three lipoprotein parameters considered necessary by the recent expert consensus guidelines from the American Diabetes Association and American College of Cardiology. The VAP Test can identify more than twice the number of lipid abnormalities (the No. 1 risk factor of heart disease) than the standard cholesterol test, and is the only cholesterol test to identify markers for Metabolic Syndrome, a precursor for diabetes.
"We're pleased to be presenting our advanced lipid profile to health care professionals at the premier conference for diabetes research and information," said Atherotech Chief Medical Officer James Ehrlich, M.D. "The conference enables us to explain one-on-one how detailed risk profiling is changing the way we evaluate and manage dyslipidemias in at-risk patients."
People with a family history or an existing condition of diabetes, high blood pressure or heart disease -- or who are already taking cholesterol lowering medication -- are candidates for the comprehensive VAP Test. In addition, those who didn't score within the desirable ranges of the standard cholesterol test (i.e. those with Triglycerides > 150, HDL < 40, LDL >130, Total Cholesterol > 200) should also opt for the more detailed VAP Test.
Atherotech representatives will be available to discuss the VAP expanded cholesterol test in booth 4202, and blood draws will be provided to qualified attendees. Test results will be returned via mail after the conference.
The VAP Test is available nationwide. For more information call 877.901.8510 or visit http://www.thevaptest.com.
About Atherotech, Inc.
Atherotech is a cardio-diagnostic company focusing on direct measurement of the comprehensive lipid panel using the company's patented VAP technology, which directly measures the cholesterol content of all lipids, components and subclasses. The VAP Test is the first cholesterol profile to comply with updated National Cholesterol Education Program ATP III recommendations for LDL measurement and the only commercially available advanced lipid profile that routinely reports all three lipoprotein parameters considered necessary by the American Diabetes Association and American College of Cardiology expert consensus guidelines. The VAP Cholesterol Test is available through national and regional diagnostic laboratories and is reimbursed by many of the largest private insurers as well as Medicare. For more information, visit http://www.thevaptest.com.
CONTACT: Dan Snyders of Armada Medical Marketing, +1-303-623-1190, ext.
230, dan@armadamedical.com, for Atherotech, Inc.; or Scott Rezek of
Atherotech, Inc., +1-205-314-7412, srezek@atherotech.com
Web site: http://www.atherotech.com/
http://www.thevaptest.com/